Digital pathology matured quickly during the pandemic, when remote work needs and temporary FDA enforcement discretion lowered the perceived barriers to whole-slide imaging. Capital followed. Roche’s May agreement to acquire PathAI for up to $1.05 billion, pending closing, is only the most recent sign of how much money is chasing the field. The most valuable… The post Leica, Indica Labs and Lunit team up as AI biomarker scoring moves toward clinical scale appeared first on Research & Development